ArticleJACC. Case reports2024
Mavacamten in Right Ventricular Outflow Tract Obstruction.
Article in JACC. Case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Unusual hypertrophic cardiomyopathy with severe right ventricular outflow tract obstruction and two septal aneurysms: a case report.BMC cardiovascular disorders · 2026Article
- Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten.JACC. Case reports · 2026Article
- Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy During Active Chemotherapy.JACC. Case reports · 2026Article
- Efficacy of mavacamten in patients with hypertrophic cardiomyopathy and mid-ventricular obstruction: case series.European heart journal. Case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Right ventricular outflow tract (RVOT) obstruction is a rare complication of ventricular hypertrophy in patients with hypertrophic cardiomyopathy (HCM). This study presents an unusual case of a patient with HCM with severe RVOT obstruction that was relieved successfully through the use of mavacamten.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.